Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Beltran Lab
Explore this Website
Home
About Us
Toggle About Us menu options
Contact Us
Job Opportunities
Videos
Affiliations
Research
Lab Team
News
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Affiliations
Research
Lab Team
News
Publications
Home
Publications
Publications
Found 11 results
Author
Title
Type
Year
Filters:
Author
is
Nanus, David M
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Beltran H
,
Park K
,
Tagawa ST
,
Macdonald T
,
Nanus DM
,
Mosquera JMiguel
,
Rubin MA
. 2012.
Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).
.
J Clin Oncol. 30(5_suppl):120.
B
Sailer V
,
Schiffman MH
,
Kossai M
,
Cyrta J
,
Beg S
,
Sullivan B
,
Pua BB
,
Lee KSteve
,
Talenfeld AD
,
Nanus DM
et al.
. 2017.
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
.
Cancer.
C
Beltran H
,
Tagawa ST
,
Park K
,
Macdonald T
,
Milowsky MI
,
Mosquera JMiguel
,
Rubin MA
,
Nanus DM
. 2012.
Challenges in recognizing treatment-related neuroendocrine prostate cancer.
.
J Clin Oncol. 30(36):e386-9.
Mateo J
,
Cheng HH
,
Beltran H
,
Dolling D
,
Xu W
,
Pritchard CC
,
Mossop H
,
Rescigno P
,
Perez-Lopez R
,
Sailer V
et al.
. 2018.
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
.
Eur Urol.
E
Galletti G
,
Matov A
,
Beltran H
,
Fontugne J
,
Mosquera JMiguel
,
Cheung C
,
MacDonald TY
,
Sung M
,
O'Toole S
,
Kench JG
et al.
. 2014.
ERG induces taxane resistance in castration-resistant prostate cancer.
.
Nat Commun. 5:5548.
I
Beltran H
,
Park K
,
Tagawa ST
,
Yelensky R
,
Lipson D
,
Frampton G
,
Stephens PJ
,
Cronin MT
,
Nanus DM
,
Mosquera JMiguel
et al.
. 2012.
Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.
.
J Clin Oncol. 30(5_suppl):110.
Robinson D
,
Van Allen EM
,
Wu Y-M
,
Schultz N
,
Lonigro RJ
,
Mosquera J-M
,
Montgomery B
,
Taplin M-E
,
Pritchard CC
,
Attard G
et al.
. 2015.
Integrative clinical genomics of advanced prostate cancer.
.
Cell. 161(5):1215-28.
N
Pisapia DJ
,
Salvatore S
,
Pauli C
,
Hissong E
,
Eng K
,
Prandi D
,
Sailer V-W
,
Robinson BD
,
Park K
,
Cyrta J
et al.
. 2017.
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.
.
JCO Precis Oncol. 2017
P
Puca L
,
Bareja R
,
Prandi D
,
Shaw R
,
Benelli M
,
Karthaus WR
,
Hess J
,
Sigouros M
,
Donoghue A
,
Kossai M
et al.
. 2018.
Patient derived organoids to model rare prostate cancer phenotypes.
.
Nat Commun. 9(1):2404.
Beltran H
,
Oromendia C
,
Danila DC
,
Montgomery B
,
Hoimes C
,
Szmulewitz RZ
,
Vaishampayan U
,
Armstrong AJ
,
Stein M
,
Pinski J
et al.
. 2018.
A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
.
Clin Cancer Res.
W
Beltran H
,
Eng K
,
Mosquera JMiguel
,
Sigaras A
,
Romanel A
,
Rennert H
,
Kossai M
,
Pauli C
,
Faltas B
,
Fontugne J
et al.
. 2015.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
.
JAMA Oncol. 1(4):466-74.